Merck Seeking Vioxx Claim Of Placebo-Level Endoscopic Ulcer Rate
Executive Summary
Merck will attempt to get a claim in its COX-2 inhibitor Vioxx labeling reflecting a placebo-like level of endoscopic ulceration, the company indicated during the Arthritis Advisory Committee meeting April 20.